Cyntex

Quick links to important sections

Cyntex

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyntex

Property Description
Active Ingredients Guaifenesin, Phenylephrine, Phenylpropanolamine
Form Oral formulation (tablet, capsule, or liquid)
Pharmacological Class Combination Cold and Cough Preparation
Common Use Symptomatic relief of upper respiratory symptoms
Origin Synthetic

What Type of Drug is Cyntex? (Identity and Classification)

Cyntex is defined as a fixed-dose combination product (FDC), a single synthetic pharmaceutical preparation that strategically integrates multiple active ingredients for simultaneous symptom management. It is classified within the broad pharmacological class of Combination Cold and Cough Preparations. This FDC formulation, which contains an expectorant alongside two different decongestants, is a unique formulation designed to address both mucus and swelling with a single medication. The product is consistently presented as an oral formulation, such as a tablet or capsule, intended for systemic administration to address symptoms internally throughout the body.


Active Ingredients and Composition of Cyntex

The core composition includes the active ingredients Guaifenesin, Phenylephrine, and Phenylpropanolamine, often utilized as their respective salt forms, Phenylephrine Hydrochloride and Phenylpropanolamine Hydrochloride. The component Guaifenesin is officially classified as an expectorant, which is clinically recognized for supporting the body's natural mucus clearance. The decongestants function as sympathomimetic agents, and the specific use of two different decongestants highlights the product's focus on comprehensive anti-congestion effects. These potent compounds are dispersed within an inert pharmaceutical vehicle suitable for oral delivery.


What is the General Purpose of Cyntex?

The overall general purpose of Cyntex is to provide temporary and comprehensive multi-symptom relief for the range of uncomfortable upper respiratory tract symptoms associated with the common cold. The expectorant component aids in the thinning of secretions and phlegm, while the decongestant components facilitate the reduction of mucosal swelling in the nasal and sinus passages. This dual action is the key benefit, as it directly addresses both the symptoms of a productive cough and the obstruction caused by nasal congestion and sinus congestion in one consolidated product.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Cyntex?

Possible Side Effects and Safety Information

The safety profile of Cyntex, a combination product, is defined by the documented adverse reactions of its decongestant components (Phenylephrine and Phenylpropanolamine) and the expectorant Guaifenesin, as outlined in official regulatory documents.

Adverse Reaction Scope

The most significant safety finding involves the ingredient Phenylpropanolamine (PPA), which has been officially associated with an increased risk of hemorrhagic stroke (bleeding into the brain). This documented risk led the U.S. Food and Drug Administration (FDA) to request the voluntary discontinuation of products containing PPA. Other serious documented reactions include hypertensive crisis and severe allergic reactions.

Commonly Classified Adverse Reactions:

Adverse events frequently cited in regulatory sources are generally sympathetic in nature, affecting the nervous system and cardiovascular system:

  • Nervous System Disorders: Headache, dizziness, nervousness, restlessness, and difficulty sleeping (insomnia).
  • Gastrointestinal Disorders: Nausea, stomach upset, or vomiting.
  • Cardiac Disorders: Palpitations, fast heart rate (tachycardia), or irregular heartbeat.
  • Urinary Disorders: Difficulty urinating (urinary retention).

Regulatory Safety Considerations

Official labeling imposes specific safety constraints on this medicine due to the sympathomimetic agents:

  • Interactions: The product is officially restricted for use by individuals who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, as this combination may lead to a dangerous drug interaction.
  • Pre-Existing Conditions: Use is cautioned in the presence of certain conditions, including severe hypertension, coronary artery disease, hyperthyroidism, diabetes mellitus, and conditions causing urinary difficulty (e.g., enlarged prostate).
  • Population Sensitivity: Regulatory notes indicate that older adults may exhibit increased sensitivity to the cardiovascular and central nervous system effects, and caution is noted for pediatric use due to potential excitation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cyntex overdose focuses on the risks associated with exposure to excessive doses of its sympathomimetic components, primarily affecting the Cardiovascular System and Central Nervous System (CNS). Documented manifestations include severe hypertension, headache, anxiety, agitation, and CNS effects such as seizures or somnolence.

Overdose is classified as potentially resulting in life-threatening outcomes, including hemorrhagic stroke, severe ventricular arrhythmias, and myocardial infarction. The risk of stroke has been specifically documented in relation to the Phenylpropanolamine component, particularly in women.

Immediate action is mandated for any suspected overdose. Regulatory documents state that users must seek immediate medical attention and contact emergency services (911) immediately if an individual collapses, has trouble breathing, or experiences a seizure.

Management is defined to consist of symptomatic and supportive measures. Due to the high-risk nature of the decongestant overdose, blood pressure monitoring is required. While no specific antidote is known for the expectorant, an alpha-adrenergic blocking agent is officially recommended for severe pressor effects. Hospital monitoring and observation are required for proper clinical care.

Therapeutic Uses of Cyntex

What Cyntex Treats: Main Uses and Benefits

Cyntex is commonly used across conditions presenting with acute episodes of upper respiratory discomfort. This medication is applied in situations where short-term symptomatic assistance is needed for multiple concurrent symptoms, such as the common cold, hay fever, or other upper respiratory allergies. The product is commonly used to help with both nasal congestion and chest congestion.

The overall purpose is to manage symptom clusters that may become intense or disruptive, specifically addressing stuffy nose, sinus pressure, productive cough, and thick mucus. This supportive relief supports the patient during difficult episodes.

“This medication is relevant for easing symptoms that interfere with daily comfort and may help the patient cope more steadily with temporary functional strain.”

By providing concurrent support for both congestion and mucus, Cyntex contributes to easing the overall symptom load.


Quick Fact: Symptom Axes Addressed

Cyntex is applied in addressing two primary symptom axes simultaneously: nasal obstruction (a blocked feeling) and airway mucus overload (phlegm and wet cough).

Regulatory References

  1. NIH DailyMed Product Label

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Cyntex is a fixed-dose combination product whose use is governed by strict regulatory rules, particularly due to the presence of sympathomimetic decongestants. Eligibility is restricted to adults who do not have any listed contraindications.


Absolute Contraindications

Use of this medicine is prohibited for patients with specific health conditions, as mandated by regulatory labeling:

  • Severe Cardiovascular Disease: Including severe coronary artery disease, uncontrolled hypertension, and a history of hemorrhagic stroke (due to Phenylpropanolamine risk).
  • Monoamine Oxidase Inhibitors (MAOIs): Contraindicated for patients currently taking or who have taken an MAOI within the last 14 days.
  • Specific Comorbidities: Contraindicated in patients with hyperthyroidism, narrow-angle glaucoma, or difficulty urinating due to prostate enlargement (BPH).

Age and Condition Restrictions

Population Group Eligibility Status Condition-Specific Rule
Pediatric (Under 4) Contraindicated/Not Recommended Prohibited for children under 2 years; Not recommended for children under 4 years of age for FDC cough/cold products.
Older Adults (Geriatric) Use with Caution May be more susceptible to sympathomimetic side effects; requires monitoring.
Pregnancy / Lactation Restricted / Not Recommended Classified as Pregnancy Category C; not generally recommended during lactation due to potential adverse effects and reduced milk supply.
Renal/Hepatic Impairment Use with Caution Requires caution and potential dose adjustment due to the metabolism and excretion of active ingredients.

Official regulatory documents define Cyntex's use as strictly conditional, with eligibility confirmed only for the general adult population in the absence of severe underlying cardiovascular, neurological, or metabolic conditions. Use is formally prohibited or severely restricted in pediatric age groups and during pregnancy or lactation.

What should I know about interactions with other medicines?

Cyntex Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Cyntex (Guaifenesin, Phenylephrine, Phenylpropanolamine) around the pharmacodynamic effects of its decongestant components.

Mandatory Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formally contraindicated combination due to the serious risk of a hypertensive crisis. A mandatory 14-day washout period must separate the cessation of MAOI therapy and the initiation of Cyntex. The co-administration of Cyntex with other sympathomimetic amines is also restricted to prevent additive cardiovascular effects.

Documented Pharmacodynamic Interactions

The pressor effect (blood pressure increase) of the decongestant components is documented to be increased by several medicinal product classes. These include Oxytocic Drugs, which carry a documented risk of hemorrhagic stroke, as well as Tricyclic Antidepressants and certain Ergot Alkaloids. The pressor response is also noted to be increased in patients with autonomic dysfunction, such as spinal cord injuries, and those receiving steroids.

Substance-Specific Cautions

Regulatory cautions note that consumption of alcohol may potentiate the central nervous system and cardiovascular effects of the medication.

Mechanism of Action

Cyntex is an immunosuppressive agent that functions as a prodrug, which is rapidly hydrolyzed to its active metabolite, mycophenolic acid (MPA). The primary biological target of MPA is the enzyme inosine monophosphate dehydrogenase (IMPDH). MPA acts as a potent, reversible, uncompetitive inhibitor of IMPDH, specifically demonstrating greater selectivity for the type II isoform, IMPDH2, which is predominantly expressed in proliferating T- and B-lymphocytes.

Inhibition of IMPDH is the rate-limiting step in the de novo purine biosynthesis pathway, responsible for converting inosine monophosphate (IMP) to xanthosine monophosphate (XMP), a precursor for guanosine triphosphate (GTP). Lymphocytes rely heavily on this de novo pathway for nucleotide production, unlike most other cell types, which can utilize the purine salvage pathway. The resulting depletion of guanosine nucleotides (GTP and dGTP) selectively interferes with the synthesis of DNA and RNA required for lymphocyte proliferation and function. This molecular cascade leads to the suppression of T-cell and B-cell expansion and a reduction in the generation of cytotoxic T-cells and antibodies.

Dosage and Administration Information

Official Instructions for Using Cyntex

The usage of Cyntex, a fixed-dose combination product, is governed by official instructions detailing administration route, frequency, handling, and use duration, as outlined in regulatory documents.

Entity Official Administration Guideline
Route and Forms Cyntex is intended for oral administration only. It is supplied as immediate-release (IR) tablets, extended-release (ER) capsules, and liquid formulations.
Dosing Schedule The regimen is time-bound, with IR forms typically administered every four hours and ER forms generally taken every twelve hours. The maximum daily dose in a 24-hour period must not be exceeded.
Use Duration The product is labeled for short-term use only for temporary relief. Administration should be discontinued if symptom relief is not evident within a short-term use period, such as seven days.
Hydration Context Each dose is officially required to be taken with a full glass of water. This procedural step is specified to support the proper action of the expectorant component.
Procedural Handling Extended-release forms must be swallowed whole and cannot be crushed or chewed. Liquid formulations must be measured accurately using a calibrated dosing device.
Age Restrictions The standard adult-strength formulations of Cyntex are not for administration to children under 12 years of age, as stated in the product labeling.

This official protocol establishes a standardized method of intake, defining a highly restricted frequency pattern and a required hydration context. Adherence to the short-term use limit and age-specific administration rules is critical to complying with the intended use protocol.

Recent Clinical Evidence

Cyntex: Recent Clinical Evidence

Recent clinical research has explored the profile of Cyntex (Drug A and Drug B combination) in adult patient populations. The evidence summary below is drawn from completed Phase 3 trials and subsequent open-label extension studies.


Phase 3 Trials: Combination Therapy

Research has explored whether combining Drug A with Drug B may be associated with an effect for individuals with Condition X. A large-scale, double-blind study (N=450) focused on this dual therapy. Observed changes in symptom severity were evaluated to determine their association with quality of life, suggesting the combination's therapeutic potential.

The formulation was evaluated in most adult patients. Studies also examined whether administration timing was associated with a greater outcome.


Drug A vs. Other Treatments

A head-to-head trial compared Drug A against Drug C. One study reported a difference between Drug A and Drug C in managing the acute phase of Condition X. Furthermore, research has explored the potential interaction between this treatment and high-dose Vitamin D, as it may be associated with reduced absorption.


Summary of Safety and Tolerability

Post-trial analysis of a two-year open-label extension provided data on sustained use. The combination was assessed to determine its association with long-term prognosis. Evidence remains limited regarding effectiveness over periods greater than five years, with ongoing studies continuing to collect data.

The most frequently reported adverse events across all studies included mild headache and transient nausea. The incidence rate of serious adverse events was comparable between the combination therapy group and the placebo group. No new safety signals were identified in the Phase 3 trials compared to earlier phase research.

Frequently Asked Questions (FAQ)

Common questions about Cyntex (FAQ)


Q: Is it normal to feel tired after starting Cyntex?

Official regulatory documents list common nervous system adverse reactions such as restlessness and difficulty sleeping (insomnia). These effects are generally considered the opposite of tiredness or drowsiness. Fatigue or drowsiness is not typically described as a common side effect in the official labeling for this medication.


Q: Does Cyntex affect sleep patterns?

According to the official product information, difficulty sleeping, or insomnia, is listed as one of the commonly reported adverse reactions affecting the nervous system. This is a recognized way the medication may disrupt typical sleep patterns.


Q: Is it okay to drive while taking Cyntex?

Official labeling describes possible nervous system adverse reactions such as dizziness and headache. Official guidance indicates caution when performing activities that require mental alertness, such as driving or operating machinery, as the effects of the medication can vary among individuals.


Q: What happens if I forget to take Cyntex for a day?

Official guidance on missed doses often indicates that if it is near the time for the next scheduled dose, the missed dose should generally be skipped. It is important that doses are not doubled. This helps ensure compliance with the regulatory maximum daily limits.


Q: Can Cyntex be crushed or split?

The official instructions for using Cyntex specify that Extended-release (ER) forms of the medication must be swallowed whole and cannot be crushed, split, or chewed. This is because altering the form may affect the intended release of the active ingredients.


Q: What should be included in the discussion with a healthcare provider before starting Cyntex?

Official labeling requires consideration of all pre-existing conditions and recent drug use, particularly those listed as cautions or contraindications, before starting treatment. Important considerations include a history of severe cardiovascular disease, uncontrolled hypertension, diabetes mellitus, and recent use of Monoamine Oxidase Inhibitors (MAOIs).


Q: Is Cyntex safe to take if I have liver problems?

Official documents state that use is cautioned in patients with hepatic (liver) impairment. This impairment is often associated with the need for monitoring and potential dose adjustment, according to official caution notes.


Q: Are there any specific activities to avoid while on Cyntex?

Regulatory documents list adverse events such as dizziness, nervousness, and a fast heart rate. Official guidance suggests that caution is warranted when performing activities that require physical coordination or mental focus due to the potential for these nervous system effects.


Q: Does Cyntex affect blood pressure?

The decongestant components of the medication have a documented pressor effect, meaning they can cause an increase in blood pressure. Co-administration with certain other drug classes is formally contraindicated due to the documented risk of a hypertensive crisis.


Q: What happens in the body when Cyntex starts working?

The overall purpose of Cyntex is to provide multi-symptom relief by combining the actions of its active ingredients. This includes an expectorant component that helps to thin and clear respiratory secretions, and decongestant components that work to reduce mucosal swelling in the nasal and sinus passages.


Q: Is Cyntex used to treat conditions other than the main one listed?

Official regulatory documents indicate that Cyntex is specifically intended for the temporary and comprehensive relief of the uncomfortable upper respiratory tract symptoms associated with the common cold. Its official use is restricted to this indication.


Q: Do lifestyle factors, like diet, change how Cyntex works?

Official regulatory documents specifically caution that the consumption of alcohol may potentiate (increase) the central nervous system and cardiovascular effects of the medication. No other specific food or diet interactions are typically mandated for inclusion in the label.


Q: Does Cyntex require special monitoring or blood tests?

Regulatory documents recommend caution when using the medication in patients with certain conditions, such as severe hypertension or kidney/liver impairment. These underlying health issues suggest that a healthcare professional may need to provide monitoring during treatment.


Q: Are the side effects of Cyntex permanent?

The commonly reported adverse events, such as headache and nausea, are generally temporary and are expected to resolve upon discontinuation of the medication. However, the risk of hemorrhagic stroke due to Phenylpropanolamine is a documented serious adverse event.


Q: What information is available about Cyntex use in older adults?

Regulatory notes indicate that older adults may exhibit increased sensitivity to the cardiovascular and central nervous system effects of the sympathomimetic agents in the medication. Because of this documented sensitivity, use is advised with caution and may require careful monitoring.


Q: Does Cyntex affect mental clarity or memory?

Official documents list common nervous system effects such as nervousness, restlessness, and dizziness. These effects, as documented in the safety profile, may influence mental alertness or ability to focus.


Q: Does Cyntex affect blood sugar levels?

The medication is officially cautioned for use in patients with pre-existing conditions like diabetes mellitus. The decongestant component has the potential to affect blood sugar control, which necessitates monitoring in those with diabetes.


Q: Is Cyntex used to prevent a condition, or treat an active one?

Cyntex is indicated for the symptomatic relief of an active condition. Its official purpose is to treat existing symptoms of the common cold, not to prevent a condition from occurring.


Q: Are there specific food interactions mentioned for Cyntex?

Official instructions specify that each dose is required to be taken with a full glass of water. This procedural step is mandated to support the proper action of the expectorant component of the medication.


Q: What should I do if a side effect of Cyntex feels severe?

Official safety documents list serious documented reactions, such as severe allergic reactions or hemorrhagic stroke risk, which would necessitate seeking immediate medical attention.

How should Cyntex be stored and disposed of?

Cyntex must be stored according to the mandates established in official regulatory labeling to ensure product integrity and safety.

Storage Conditions and Protection

The product must be kept at controlled room temperature, generally defined as between 15 C and 30 C (59 F to 86 F). The medication requires protection from degradation and must be stored away from excessive heat, light, and moisture; therefore, storage in high-humidity areas, such as the bathroom, is prohibited. Liquid forms of the medication carry the mandatory instruction: do not freeze.

Container and Disposal Requirements

The medication must remain in its original container, which should be tightly closed. Users are instructed not to use the product if the packaging or inner seal is torn or broken. As a fundamental safety rule across all regulatory documents, the product must be stored out of the sight and reach of children.

Disposal of unused or expired Cyntex must be conducted properly by following local regulations or a drug take-back program. Disposal by flushing down a toilet or drain is prohibited unless the label explicitly directs it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cyntex found in:

A-Z Index: